Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil

Rheumatology

Volumn 49, Issue 3, 2009, Pages 490-500

  Launay, David ^a,b,c,d   Sitbon, Olivier ^a,b,c   Le Pavec, Jérôme ^a,b,c   Savale, Laurent ^a,b,c   Tchérakian, Colas ^a,b,c   Yaïci, Azzedine ^a,b,c   Achouh, Lara ^a,b,c   Parent, Florence ^a,b,c   Jais, Xavier ^a,b,c   Simonneau, Gérald ^a,b,c   Humbert, Marc ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d UNIV LILLE   (France)

Author keywords

Endothelin receptor antagonist; Haemodynamics; Pulmonary hypertension; Survival; Systemic sclerosis

Indexed keywords

BOSENTAN; PROSTACYCLIN; PROSTANOID; SILDENAFIL;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; HEMODYNAMICS; HUMAN; MALE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SIDE EFFECT; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; EPOPROSTENOL; EXERCISE TEST; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; MIDDLE AGED; PIPERAZINES; PURINES; RECEPTOR, ENDOTHELIN A; SCLERODERMA, SYSTEMIC; SULFONAMIDES; SULFONES; TREATMENT OUTCOME;

EID: 77950545229     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep398     Document Type: Article

References (42)

1. Steen V. Advancements in diagnosis of pulmonary arterial hypertension in scleroderma. Arthritis Rheum 2005;52: 3698-700.
2. Hachulla E, Gressin V, Guillevin L et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
3. Hachulla E, de Groote P, Gressin V et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009;60: 1831-9.
4. Launay D, Mouthon L, Hachulla E et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol 2007;34:1005-11.
5. Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 2005;24:1626-31.
6. Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003;167:580-6.
7. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
8. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344-50.
9. Hachulla E, Carpentier P, Gressin V et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French Itiné rAIR-Sclé rodermie study. Rheumatology 2009;48:304-8.
10. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66: 940-4.
11. Launay D, Hachulla E, Hatron PY et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J Rheumatol 2001;28:2252-6.
12. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
13. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-9.
14. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
15. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
16. Galié N, Olschewski H, Oudiz RJ et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-9.
17. Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
18. Sitbon O, McLaughlin VV, Badesch DB et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005;60: 1025-30.
19. McLaughlin VV, Sitbon O, Badesch DB et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9.
20. Joglekar A, Tsai FS, McCloskey DA, Wilson JE, Seibold JR, Riley DJ. Bosentan in pulmonary arterial hypertension secondary to scleroderma. J Rheumatol 2006;33:61-8.
21. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40.
22. Williams MH, Das C, Handler CE et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006;92:926-32.
23. Masi AT, Rodnan GP, Medsger TA Jr et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23: 581-90.
24. Cohen H, Chahine C, Hui A, Mukherji R. Bosentan therapy for pulmonary arterial hypertension. Am J Health Syst Pharm 2004;61:1107-19.
25. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
26. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OE, Peslin R, Yernault JC. Standardization of the measurements of transfer factor (diffusing capacity). Report working party standardization of lung functiontests, European community for steel and coal. Official statement of the European society. Eur Respir J 1993;6: 5-52.
27. Launay D, Remy-Jardin M, Michon-Pasturel U et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006;33: 1789-801.
28. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351: 1425-36.
29. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
30. Sitbon O, Brenot F, Denjean A et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:384-9.
31. Chemla D, Castelain V, Hervé P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002;20:1314-31.
32. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006;27:589-95.
33. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
34. Schoindre Y, Meune C, Dinh-Xuan AT, Avouac J, Kahan A, Allanore Y. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J Rheumatol 2009;36:1481-5.
35. Avouac J, Wipff J, Kahan A, Allanore Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2008;67: 808-14.
36. Fisher MR, Mathai SC, Champion HC et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006;54: 3043-50.
37. Condliffe R, Kiely DG, Peacock AJ et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179:151-7.
38. Mathai SC, Hummers LK, Champion HC et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009;60:569-77.
39. Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
40. Hachulla AL, Launay D, Gaxotte V et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009;68:1878-84.
41. Dorfmuller P, Humbert M, Perros F et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007;38:893-902.
42. Allanore Y, Borderie D, Avouac J et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008;58:284-91.